JUL 22, 2017 8:24 AM PDT

Scientists Train Immune Cells to Gobble Up Cancer

WRITTEN BY: Xuan Pham

Cancer cells evolved to have cunning strategies to protect themselves against the body’s defenses. One of these strategies involve expressing the “don’t eat me tag” so as to fool immune cells into treating it as healthy cells. But now, scientists have wised up to cancer’s tricks and have re-engineered immune cells to recognize and attack these disguised cancer cells.

Image credit: Pixabay.com

The body is equipped with immune cells that recognize and attack cells that it perceives as foreign invaders. Macrophages are among these fighter cells. Considered the “first responders,” these cells gobble up diseased and foreign bodies to protect the body. Its name derives from the Greek for “big eater.”

Healthy cells protect themselves from the macrophage’s destruction by expressing CD47, a surface protein that serves as a “marker of self.” But because cancer cells are mutated versions of healthy cells, they also express CD47. Thus, instead of attacking cancer cells, macrophages let these invaders go untouched because they’ve been tricked into thinking these cells are part of the normal system.

Knowing this trickery, scientists at the University of Pennsylvania sought to help macrophages better distinguish between healthy and cancerous cells. They did this by blocking the interaction of CD47 to surface proteins on the macrophages, known as SIRPA.

"Our new approach takes young and aggressive macrophages from the bone marrow of a human donor and removes a key safeguard that cancer cells have co-opted to prevent them from being engulfed," said Cory Alvey, the study’s lead author.

But there was a problem. While modified macrophages would recognize cancer cells as foreign and launched attacks on these, it also attacked healthy cells in a similar fashion. Indeed, previous studies in mice showed that blocking the interaction between CD47 and SIRPA did decrease cancer cells. But the mice also lost healthy blood cells, became anemic, and some even died.

To solve this problem, the team introduced antibodies that were specific to cancer cells. These would allow macrophages to zero in on the cancer cells that are now unmasked and targeted.

"Combined with cancer-specific targeting antibodies, these engineered macrophages swarm into solid tumors and rapidly drive regression of human tumors without any measurable toxicity,” said Alvey.

The team showed that with just two injections, dime-sized tumors shrank by 80 percent. Furthermore, the cancer cell count decreased by 100-fold. "The big surprise," said Dennis Discher, "is that injected macrophages circulate all around the body but accumulate only within the tumors where they engorge on cancer cells." Discher is a professor in Penn Engineering's Department of Chemical and Bimolecular Engineering, and the study’s senior author.

"Safety thus far is likely a consequence of both the relatively small number of engineered macrophages that are injected and their sequestration into the tumors, away from most healthy cells," Discher said.

“The first phase of clinical trials are tests of human safety, so this is a promising start," Alvey said. "The potency of these engineered macrophages is relatively clear, but the crucial issue is how to maximize the anticancer effects while minimizing side effects, namely the engulfment of normal cells." In addition, the team is working to make the anticancer effects longer-lasting.

Additional sources: University of Pennsylvania

 

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
OCT 05, 2020
Cancer
Does Having an Appendectomy Increase Your Risk for Cancer?
OCT 05, 2020
Does Having an Appendectomy Increase Your Risk for Cancer?
Cancer research is more than just the study of diagnostics and novel therapies. Researchers also investigate the causes ...
OCT 13, 2020
Immunology
Early Tips For Cell & Gene Therapy Regulatory Compliance
OCT 13, 2020
Early Tips For Cell & Gene Therapy Regulatory Compliance
Cell and gene therapies hold great promise for improved health outcomes. Now is the time to advance life-saving research ...
OCT 16, 2020
Cancer
Chronic jet lag raises cancer risk
OCT 16, 2020
Chronic jet lag raises cancer risk
We all know how horrible it feels to have a bad night of sleep. That feeling is only intensified with jet lag because ou ...
OCT 20, 2020
Clinical & Molecular DX
Non-coding RNA As A Barometer For Liver Health
OCT 20, 2020
Non-coding RNA As A Barometer For Liver Health
October is liver cancer awareness month — a month dedicated to educating people about the risk factors and prevent ...
OCT 26, 2020
Cancer
Investigating the Receptor Protein FPR1 in Brain Cancer
OCT 26, 2020
Investigating the Receptor Protein FPR1 in Brain Cancer
Amongst the more common targets for cancer therapies are cell surface receptors. These receptors are proteins – us ...
NOV 29, 2020
Cell & Molecular Biology
Engineering 'Smart' Cells to Kill Cancer
NOV 29, 2020
Engineering 'Smart' Cells to Kill Cancer
Cancer researchers have long been searching for a way to target cancer cells while ignoring healthy cells. A team of sci ...
Loading Comments...